Adeena Musheer, Operations Coordinator and Educational Committee Member at MedNews Week, shared on X:
“Can PD-1 blockade meaningfully change outcomes in cervical cancer?
Our meta-analysis of camrelizumab found a pooled objective response rate of 60%, highlighting substantial antitumor activity.
Read more: PD-1 Inhibition With Camrelizumab in Cervical Cancer
Other articles about cervical cancer on OncoDaily.